Journals and Media

Information Resources

Aunt - Women’s’ Imaging - DG News
Elsevier Journal Alerts - The Breast
Hologic ANZ
Practice Update

Jenescreen - free BRCA founder mutation testing for Jews


The JeneScreen research project is open to residents of Sydney and Melbourne, and will test for the three BRCA faults that are common in the Jewish population. Please click here for more information about how you can be involved in the research project.

  • Triple-Modality Screening Trial for Familial Breast Cancer


    Triple-Modality Screening Trial for Familial Breast Cancer Underlines the Importance of Magnetic Resonance Imaging and Questions the Role of Mammography and Ultrasound Regardless of Patient Mutation Status, Age, and Breast Density


    To evaluate the breast cancer screening efficacy of mammography, ultrasound, and magnetic resonance imaging (MRI) in a high-risk population and in various population subgroups.

    Patients and Methods

    In a single-center, prospective, nonrandomized comparison study, BRCA mutation carriers and women with a high familial risk (> 20% lifetime risk) for breast cancer were offered screening with mammography, ultrasound, and MRI every 12 months. Diagnostic performance was compared between individual modalities and their combinations. Further comparisons were based on subpopulations dichotomized by screening rounds, mutation status, age, and breast density.


    There were 559 women with 1,365 complete imaging rounds included in this study. The sensitivity of MRI (90.0%) was significantly higher (P < .001) than that of mammography (37.5%) and ultrasound (37.5%). Of 40 cancers, 18 (45.0%) were detected by MRI alone. Two cancers were found by mammography alone (a ductal carcinoma in situ [DCIS] with microinvasion and a DCIS with < 10-mm invasive areas). This did not lead to a significant increase of sensitivity compared with using MRI alone (P = .15). No cancers were detected by ultrasound alone. Similarly, of 14 DCISs, all were detected by MRI, whereas mammography and ultrasound each detected five DCISs (35.7%). Age, mutation status, and breast density had no influence on the sensitivity of MRI and did not affect the superiority of MRI over mammography and ultrasound.


    MRI allows early detection of familial breast cancer regardless of patient age, breast density, or risk status. The added value of mammography is limited, and there is no added value of ultrasound in women undergoing MRI for screening.

    To read more please go to the article.

  • Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy aft


    Ductal carcinoma in situ (DCIS) affects around 8000 women a year in the UK.1 Since the introduction of mammographic screening, the incidence of DCIS has increased and it now represents around 20% of all new screen detected breast cancers.

    To read more please go to the article.

  • An overview of mammographic density and its association with breast cancer


    In 2017, breast cancer became the most commonly diagnosed cancer among women in the US. After lung cancer, breast cancer is the leading cause of cancer-related mortality in women. The breast consists of several components, including milk storage glands, milk ducts made of epithelial cells, adipose tissue, and stromal tissue. Mammographic density (MD) is based on the proportion of stromal, epithelial, and adipose tissue. Women with high MD have more stromal and epithelial cells and less fatty adipose tissue, and are more likely to develop breast cancer in their lifetime compared to women with low MD. Because of this correlation, high MD is an independent risk factor for breast cancer. Further, mammographic screening is less effective in detecting suspicious lesions in dense breast tissue, which can lead to late-stage diagnosis. Molecular differences between dense and non-dense breast tissues explain the underlying biological reasons for why women with dense breasts are at a higher risk for developing breast cancer. The goal of this review is to highlight the current molecular understanding of MD, its association with breast cancer risk, the demographics pertaining to MD, and the environmental factors that modulate MD. Finally, we will review the current legislation regarding the disclosure of MD on a traditional screening mammogram and the supplemental screening options available to women with dense breast tissue.

    To read more please go to the article.

  • How many people will be diagnosed with cancer in your suburb in 2018?


    More than 46,000 people in NSW will be told they have cancer in 2018, official projections show.

    The sobering forecast also predicted the number of new breast, lung, bowel cancer and melanoma patients who will be diagnosed across every Sydney local government area (LGA) this year.

    To read more please go to the article.

  • Pollution linked to higher breast cancer risk in biggest study yet


    Women living in areas with high air pollution are more likely to have dense breasts, boosting their chances of developing breast cancer, a major new study has found.

    Breast density has been shown to have a strong link to breast cancer. Women with the most dense breasts — the highest proportion of fibroglandular, rather than fatty, tissue — are three to five times more likely to develop the disease than those with the least.

    To read more please go to the article.

  • Epithelial Proliferation in Biopsies Tied to Breast Cancer Risk


    Women with progressive epithelial proliferation across serial biopsies have an increased risk of breast cancer, while those with regression of initial proliferative disease without atypia face a lower risk compared with no change, researchers have found.

    To read more please go to the article.

  • Atypical Hyperplasia of the Breast — Risk Assessment and Management Options


    Lynn C. Hartmann, M.D., Amy C. Degnim, M.D., Richard J. Santen, M.D., William D. Dupont, Ph.D., and Karthik Ghosh, M.D

    Breast biopsies are commonly performed to evaluate mammographic or palpable findings that are of concern, and the majority reveal benign findings. More than 1 million of the breast biopsies that are performed annually in the United States are found to be benign.1 On the basis of the histologic findings, it is possible to stratify women with benign biopsy findings into groups with significantly different risks of later breast cancer.2,3 Atypical hyperplasia is a high-risk benign lesion that is found in approximately 10% of biopsies with benign findings.4 In this article, we examine these benign lesions because they have special importance as a predictor of future breast cancer. There are two types of atypical hyperplasia, as classified on the basis of microscopic appearance: atypical ductal hyperplasia and atypical lobular hyperplasia; these occur with equal frequency and confer similar risks of later breast cancer ( Table 1 Risk of Breast Cancer among Women with Atypical Hyperplasia.). 2,3,9,10 Thus, throughout this article, the varieties will be referred to together as “atypical hyperplasia.”

    To read more please go to the article.

  • Exercise is best for reducing breast cancer recurrence


    By Ana Sandoiu

    Breast cancer survival rates are very high compared with other forms of cancer, but in some cases, the cancer does comes back. New research highlights key recommendations that breast cancer survivors can incorporate into their lifestyle so as to reduce the risk of breast cancer recurrence.

    To read more please go to the article.

  • Fighting Triple-Negative Breast Cancer With The Help Of Vitamin D


    In research published in The Journal of Cell Biology, a team led by Susana Gonzalo, Ph.D., assistant professor of biochemistry and molecular biology at Saint Louis University, has discovered a molecular pathway that contributes to triple-negative breast cancer, an often deadly and treatment resistant form of cancer that tends to strike younger women. In addition, Gonzalo and her team identified vitamin D and some protease inhibitors as possible new therapies and discovered a set of three biomarkers that can help to identify patients who could benefit from the treatment.

    To read more please go to the article.